| Vasant Narasimhan |
Dr. Vasant Narasimhan, MD, is a Chairman at African Parks Network, a Chief Executive Officer at Novartis International AG, a Chief Executive Officer at Novartis AG, a Chief Executive Officer at Novartis Pharma AG, a Chief Executive Officer at Novartis Korea Ltd., a Chief Executive Officer at Novartis Pharma BV, a Chief Executive Officer at Novartis Pharmaceuticals Corp. and a Member at National Academy of Medicine (United States). He is on the Board of Directors at Novartis Foundation and Pharmaceutical Research & Manufacturers of America. Dr. Narasimhan was previously employed as a Global Head-Development by Sandoz Pharmaceuticals AG, a Global Head-Development by Novartis Pharmaceuticals, a Global Head-Biopharmaceuticals by Sandoz International GmbH, and a Global Head-Development by Novartis Vaccines & Diagnostics, Inc. He also served on the board at Novartis Institute for Functional Genomics, Inc. He received his undergraduate degree from The University of Chicago, a graduate degree from Harvard Kennedy School of Government and a doctorate degree from Harvard Medical School. |
| Shreeram Aradhye |
Shreeram Aradhye currently works at Valo Health LLC, as Director, Novartis AG, as Chief Medical Officer & President-Development from 2022, and Novartis Pharma AG, as President, Development & Chief Medical Officer from 2022. Dr. Aradhye also formerly worked at Axcella Health, Inc., as Independent Director from 2020 to 2022, Dicerna Pharmaceuticals, Inc., as Chief Medical Officer & Executive Vice President from 2020 to 2022, the University of Pennsylvania, as Assistant Professor, Sandoz International GmbH, as Head-Global Clinical Development & Medical Affairs from 2009 to 2011, Novartis Pharmaceuticals Corp., as Chief Medical Officer from 2017 to 2019, and Novartis India Ltd., as Head-Global Development from 2011 to 2012. Dr. Aradhye received his undergraduate degree from All India Institute of Medical Sciences. |
| Michelle Weese |
Michelle Weese was the founder of Stratigence LLC, founded in 2009, serving as Chief Executive Officer from 2009 to 2019. Ms. Weese is currently the Chief Corporate Affairs Officer at Novartis AG, starting in 2023. Former positions include Independent Director at Krispy Kreme, Inc. from 2020 to 2025, Executive Vice President-Corporate Affairs at Bristol Myers Squibb Co. from 2021 to 2023, General Secretary-North America at Danone SA from 2019 to 2021, and Global Head-Corporate Communications at Mars, Inc. from 1999 to 2009. Education includes an undergraduate degree from Georgia State University. |
| Robert Kowalski |
Robert Kowalski currently works at Novartis AG, as Chief People & Organization Officer from 2021. Dr. Kowalski also formerly worked at Novartis Corp., as President, Novartis Pharmaceuticals Corp., as Executive VP & Global Head-Regulatory Affairs from 2018 to 2021, and Novartis Pharma AG, as Senior Vice President & Head-Regulatory Affairs from 2015 to 2017. Dr. Kowalski received his undergraduate degree and doctorate degree from the University of Wisconsin. |
| Kees Roks |
Mr. Kees Roks is a Chief Audit Officer at Novartis AG. He is on the Board of Directors at Junior Achievement Europe. He received his undergraduate degree from Technische Universiteit Eindhoven. |
| Ingrid Zhang |
Ms. Ingrid Zhang is an Independent Director at Mettler-Toledo International, Inc. and a Chief Commercial Officer-International at Novartis AG. She is on the Board of Directors at Mettler-Toledo International, Inc. |
| Karen L. Hale |
Karen L. Hale currently works at Novartis AG, as Chief Legal & Compliance Officer from 2025, Illinois State Bar Association, as Member, and The Virginia Bar Association, as Member. Ms. Hale also formerly worked at Abbott Laboratories, as Divisional VP-Commercial Litigation from 2006 to 2012, AbbVie, Inc., as Vice President & Deputy General Counsel from 2019 to 2021, and Sidley & Austin, as Associate Attorney. Ms. Hale received her undergraduate degree from Duke University and graduate degree from The College of William & Mary. |
| Aharon Gal |
Aharon Gal currently works at Novartis AG, as Chief Strategy & Growth Officer from 2022. Dr. Gal also formerly worked at The Boston Consulting Group, Inc., as Manager, Canon U.S. Life Sciences, Inc., as Vice President from 2003 to 2004, and Sanford C. Bernstein & Co. LLC, as Senior Analyst. Dr. Gal received his undergraduate degree from Emory University and doctorate degree from Massachusetts Institute of Technology. |
| Korab Zuka |
Korab Zuka currently works at Novartis AG, as Chief Sustainability Officer. |
| Giovanni Caforio |
Giovanni Caforio currently works at Bristol-Myers Squibb Romania SRL, as Chairman & Chief Executive Officer, Novartis AG, as Chairman from 2025, Stryker Corp., as Independent Director from 2020, The Business Roundtable, as Member, European Federation of Pharmaceutical Industries & Assns, as Trustee, Hun School of Princeton, Inc., as Trustee, and TJ Holdings LLC, as Member. Dr. Caforio also formerly worked at Pharmaceutical Research & Manufacturers of America, as Co-Chairman from 2019 to 2020, Bristol Myers Squibb Co., as Executive Chairman from 2023 to 2024, Capital Health System, Inc., as Director, National Pharmaceutical Council, as Director, CEO Roundtable on Cancer, Inc., as Member, and Abbott Laboratórios Lda., as General Manager from 1988 to 2000. Dr. Caforio received his doctorate degree in 1988 from Università degli Studi di Roma Tor Vergata. |
| Harry Werner Kirsch |
Harry Werner Kirsch currently works at Novartis Pharma KK, as Vice Chairman, Novartis Vaccines & Diagnostics, Inc., as Director, Novartis Institutes for Biomedical Research, Inc., as Director, Novartis International AG, as Member-Supervisory Board, and Novartis AG, as Chief Financial Officer from 2013. Mr. Kirsch also formerly worked at GlaxoSmithKline Consumer Healthcare Pte Ltd., as Director from 2015 to 2018, Procter & Gamble Co., as CFO-Global Pharmaceutical Business, and Novartis Pharma AG, as Chief Financial Officer-Pharmaceuticals from 2010 to 2013. |
| Steffen Lang |
Dr. Steffen Lang is a President-Operations at Novartis AG. He is on the Board of Directors at Bachem Holding AG. He received his graduate degree from Ruprecht-Karls-Universität Heidelberg and a doctorate degree from Swiss Federal Institute of Technology. |
| James E. Bradner |
James E. Bradner is the founder of Tensha Therapeutics, Inc. (2011), Acetylon Pharmaceuticals, Inc. (2008), C4 Therapeutics, Inc. (2015), TetraLogic Research & Development Corp. (2008), and Syros Pharmaceuticals, Inc. (2011). Titles held included Director at Acetylon Pharmaceuticals, Inc. and TetraLogic Research & Development Corp., and Director at Syros Pharmaceuticals, Inc. from 2011 to 2015. Current jobs include Chairman at Novartis Institute for Functional Genomics, Inc., Director at Foundation for the National Institutes of Health, Inc. since 2023, Executive VP-Research & Development at Amgen, Inc. starting in 2024, Associate Professor at Harvard Medical School, and Advisor at Longwood Fund Management LLC. Former jobs include Associate Director-Therapeutics Science Centre at The Broad Institute, Inc., Member-Supervisory Board at QIAGEN NV in 2015, Member of the American Chemical Society, Member of the American Society of Hematology, and President at Novartis Institutes for Biomedical Research, Inc. from 2016 to 2022. Education includes an undergraduate degree from Harvard University conferred in 1994 and a doctorate from Pritzker School of Medicine. |
| Patrick Horber |
Patrick Horber currently works at AbbVie Pharmaceuticals GmbH, as Managing Director and Novartis AG, as President-International from 2023. Dr. Horber also formerly worked at Abbott AG, as Managing Director in 2012, Verband Forschender Arzneimittelhersteller eV, as Director from 2016 to 2019, AbbVie AG, as Managing Director from 2013 to 2015, AbbVie Deutschland GmbH & Co. KG, as Co-Managing Director & Vice President from 2015 to 2019, AbbVie, Inc., as President-Immunology & Senior Vice President in 2023, and Interpharma, as Member-Presidents Bureau in 2015. Dr. Horber received his doctorate degree from the University of Zurich. |
